<DOC>
	<DOCNO>NCT02698267</DOCNO>
	<brief_summary>The primary objective study assess effect cytochrome P450 ( CYP ) 3A4 inhibition pharmacokinetics ( PK ) BIIB074 . The secondary objective study assess safety tolerability BIIB074 co-administered strong CYP3A4 inhibitor ass effect CYP3A4 inhibition PK 3 metabolite BIIB074 ( CNV3000497 [ M13 ] , CNV2283325 [ M14 ] , CNV2288584 [ M16 ] ) .</brief_summary>
	<brief_title>Effect Itraconazole Pharmacokinetics BIIB074</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Key Body mass index 18 29 kg/m2 , inclusive , body weight ≥50 kg male ≥45 kg female . Male postmenopausal surgically sterile female . Must good health determine Investigator ( designee ) , base medical history screening evaluation . Key Females childbearing potential . Other unspecified reason , opinion Investigator Sponsor , make subject unsuitable enrollment . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>